134 related articles for article (PubMed ID: 10375203)
1. A model to monitor the efficacy of alendronate treatment in women with osteoporosis using a biochemical marker of bone turnover.
Garnero P; Darte C; Delmas PD
Bone; 1999 Jun; 24(6):603-9. PubMed ID: 10375203
[TBL] [Abstract][Full Text] [Related]
2. Comparison of bone and total alkaline phosphatase and bone mineral density in postmenopausal osteoporotic women treated with alendronate.
Watts NB; Jenkins DK; Visor JM; Casal DC; Geusens P
Osteoporos Int; 2001; 12(4):279-88. PubMed ID: 11420777
[TBL] [Abstract][Full Text] [Related]
3. Early changes in biochemical markers of bone turnover predict bone mineral density response to antiresorptive therapy in Korean postmenopausal women with osteoporosis.
Kim SW; Park DJ; Park KS; Kim SY; Cho BY; Lee HK; Shin CS
Endocr J; 2005 Dec; 52(6):667-74. PubMed ID: 16410657
[TBL] [Abstract][Full Text] [Related]
4. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB
J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
[TBL] [Abstract][Full Text] [Related]
5. A negative feedback model for a mechanism based description of longitudinal observations. Application for bone turnover biomarkers.
Boroujerdi MA; Schmidt S
Methods Inf Med; 2013; 52(6):484-93. PubMed ID: 23907233
[TBL] [Abstract][Full Text] [Related]
6. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
[TBL] [Abstract][Full Text] [Related]
7. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
Murphy MG; Weiss S; McClung M; Schnitzer T; Cerchio K; Connor J; Krupa D; Gertz BJ;
J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
[TBL] [Abstract][Full Text] [Related]
8. Determinants of one-year response of lumbar bone mineral density to alendronate treatment in elderly Japanese women with osteoporosis.
Iwamoto J; Takeda T; Sato Y; Uzawa M
Yonsei Med J; 2004 Aug; 45(4):676-82. PubMed ID: 15344210
[TBL] [Abstract][Full Text] [Related]
9. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.
Ettinger B; San Martin J; Crans G; Pavo I
J Bone Miner Res; 2004 May; 19(5):745-51. PubMed ID: 15068497
[TBL] [Abstract][Full Text] [Related]
10. Monitoring individual response to hormone replacement therapy with bone markers.
Delmas PD; Hardy P; Garnero P; Dain M
Bone; 2000 Jun; 26(6):553-60. PubMed ID: 10831925
[TBL] [Abstract][Full Text] [Related]
11. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial.
Lems WF; Lodder MC; Lips P; Bijlsma JW; Geusens P; Schrameijer N; van de Ven CM; Dijkmans BA
Osteoporos Int; 2006; 17(5):716-23. PubMed ID: 16463007
[TBL] [Abstract][Full Text] [Related]
12. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group.
Ravn P; Clemmesen B; Christiansen C
Bone; 1999 Mar; 24(3):237-44. PubMed ID: 10071916
[TBL] [Abstract][Full Text] [Related]
13. Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International.
Sambrook PN; Geusens P; Ribot C; Solimano JA; Ferrer-Barriendos J; Gaines K; Verbruggen N; Melton ME
J Intern Med; 2004 Apr; 255(4):503-11. PubMed ID: 15049885
[TBL] [Abstract][Full Text] [Related]
14. Monitoring alendronate therapy for osteoporosis.
Braga de Castro Machado A; Hannon R; Eastell R
J Bone Miner Res; 1999 Apr; 14(4):602-8. PubMed ID: 10234582
[TBL] [Abstract][Full Text] [Related]
15. Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy.
Fink E; Cormier C; Steinmetz P; Kindermans C; Le Bouc Y; Souberbielle JC
Osteoporos Int; 2000; 11(4):295-303. PubMed ID: 10928218
[TBL] [Abstract][Full Text] [Related]
16. The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin.
Tascioglu F; Colak O; Armagan O; Alatas O; Oner C
Rheumatol Int; 2005 Nov; 26(1):21-9. PubMed ID: 15688191
[TBL] [Abstract][Full Text] [Related]
17. Bisphosphonates for prevention of postmenopausal osteoporosis.
Ravn P
Dan Med Bull; 2002 Feb; 49(1):1-18. PubMed ID: 11894721
[TBL] [Abstract][Full Text] [Related]
18. Early changes in urinary cross-linked N-terminal telopeptides of type I collagen level correlate with 1-year response of lumbar bone mineral density to alendronate in postmenopausal Japanese women with osteoporosis.
Iwamoto J; Takeda T; Sato Y; Uzawa M
J Bone Miner Metab; 2005; 23(3):238-42. PubMed ID: 15838627
[TBL] [Abstract][Full Text] [Related]
19. Biochemical markers for prediction of 4-year response in bone mass during bisphosphonate treatment for prevention of postmenopausal osteoporosis.
Ravn P; Thompson DE; Ross PD; Christiansen C
Bone; 2003 Jul; 33(1):150-8. PubMed ID: 12919710
[TBL] [Abstract][Full Text] [Related]
20. [Alendronate in postmenopausal women with osteopenia and osteoporosis: effects on bone mineral density during treatment and after withdrawal].
Jiang Y; Li M; Xia W; Xing X; Yu W; Tian J; Meng X; Zhou X
Zhonghua Yi Xue Za Zhi; 2002 Sep; 82(18):1254-6. PubMed ID: 12425805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]